IceCure enrolls first patients in US study of ProSense for low-risk breast cancer
ICCM•IceCure Medical enrolled the first two patients in its ChoICE post-marketing study of ProSense cryoablation for low-risk breast cancer. The study aims to include approximately 400 patients at up to 30 US sites.
1. Study enrollment begins
IceCure Medical enrolled the first two patients in its ChoICE post-marketing study of ProSense cryoablation for low-risk breast cancer. The study targets approximately 400 patients across up to 30 US sites to generate real-world evidence on the FDA-cleared treatment; participating centers are expected to offer ProSense commercially to eligible patients outside the study.
